Calcitonin oral - Bone Medical

Drug Profile

Calcitonin oral - Bone Medical

Alternative Names: BN 002; Capsitonin

Latest Information Update: 02 Sep 2015

Price : $50

At a glance

  • Originator Bone Medical
  • Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Calcitonin stimulants; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Osteoarthritis
  • Discontinued Osteoporosis

Most Recent Events

  • 28 Jan 2013 Phase-II clinical trials in Osteoarthritis in Australia (PO)
  • 20 Jul 2012 The European Medicines Agency recommended that due to an increased risk of cancer associated with long-term use, calcitonin medicines should only be used for the shortest possible time using the minimum effective dose .
  • 19 Aug 2009 Preclinical trials in Osteoarthritis in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top